Should you start a weight management clinic?
The regulatory content is addressed elsewhere in this library, in the verification duties, the remote prescribing standards and the two-registration structure. This guide assumes that material and addresses the build.
It should nonetheless begin with the question owners skip. The category carries the heaviest scrutiny in private pharmacy, and the entry test is not whether demand exists, since it plainly does, but whether the pharmacy can operate genuine verification and genuine monitoring at the volume it intends to reach, with a prescriber who can genuinely decline.
That threshold is deliberately awkward, because a service which cannot meet it will fail in a manner which damages more than the service. It is also now written down. The regulator's themed review of 24 April 2026 sets out six recommended actions covering risk assessment, due diligence upon third party prescribing services, independent verification, individual clinical suitability with specific regard to vulnerable groups including those with eating disorders, thorough documentation and ongoing follow up, and the inspection framework published on 13 January 2026 makes failure to verify weight, height or BMI an inspection failure. Both are set out in the verification duties article, and a build plan which does not answer all six is not a build plan. A pharmacy whose weight management arm attracts regulatory attention has a problem across its whole registration, and, as the payments material sets out, across its acquiring relationships too. An owner unable to answer the entry test affirmatively should not proceed, and the honest version of that answer sometimes arrives only after modelling the costs below.
What are the four structural choices?
Four decisions determine cost, control and reversibility, and each is considerably easier to make than to unmake.
| Choice | Options | What it determines |
|---|---|---|
| Prescribing capacity | Employed prescriber, contracted prescriber, partner clinic, or pharmacist prescriber in-house | Fixed versus variable cost, clinical control, continuity, and whether capacity scales with demand |
| Consultation model | In-person, remote asynchronous with synchronous escalation, or hybrid | Premises requirements, geographic reach, verification difficulty and the standards which apply |
| Corporate structure | Single registered pharmacy, or separate clinic entity alongside the pharmacy | Regulatory footprint, prescriber independence, and how the arrangement reads to underwriters and purchasers |
| Supply arrangement | Own stock, wholesaler account with buffer, or supply via partner | Working capital, exposure to shortage, and control over continuity of treatment |
The choice which owners underestimate is the first. Contracted prescribing converts a fixed cost into a variable one and is the obvious route at low volume, whilst it also places the clinical decision, the availability and the escalation response outside the business. Where a service grows, that arrangement is frequently the constraint rather than the enabler, and renegotiating it under demand pressure is a poor position from which to negotiate.
What does it cost to set up?
Published figures for this are unreliable, because they conflate very different models, so the honest approach is to build the estimate from components. Five are unavoidable.
Prescriber capacity, whether as salary, sessional rates or a contracted arrangement, which is ordinarily the largest single line and the one which scales with volume.
The consultation and record system, capable of holding the questionnaire, the verification artefacts, the prescriber's reasoning and the review intervals in one place. This is the evidence pack the frameworks expect, and a service running on forms and email will discover that at the least convenient moment.
Verification arrangements, being the independent confirmation the category requires rather than self-report, whether through records requests, GP correspondence, in-person measurement or a verification provider.
Clinical governance, comprising protocols, the escalation policy, the audit schedule and the documentation an inspector would read.
Supply, comprising initial stock or the arrangement replacing it, including cold chain where the product requires it.
Two further lines are commonly omitted and should not be. Staff time to operate the service, which is real capacity taken from an already stretched team, and the period before revenue, since a service takes months to build a cohort large enough to matter.
What order do you build it in?
Services fail in a predictable order, and it is the reverse of the order they are built in. The natural instinct is to start with the thing which produces revenue, meaning the landing page, the pricing and the advertising, then to add the consultation, then to arrange a prescriber, and to formalise the governance last because it produces nothing. That sequence guarantees the failure, because each layer constrains the one beneath it. A funnel built before the clinical protocol will ask the wrong questions. A consultation designed before the prescriber is appointed will not match how that prescriber works. A verification step added after launch has to be retrofitted into a flow which patients are already using, and every existing patient has been assessed without it. The correct sequence is governance and protocol, then prescriber arrangements, then the consultation and record system, then verification workflows, then supply, then pricing, and promotion last. It feels slower and it is not, because the alternative is a launch which stalls at the first serious question from an acquirer, a certifier or an inspector, at which point the rebuild happens anyway, under time pressure, with patients already in treatment.
How do you find a prescriber?
This is the practical bottleneck for most pharmacies, and the question is less about finding one than about defining the relationship properly.
Four points determine whether the arrangement works. Independence must be genuine and structural, meaning the prescriber's decision cannot be influenced by the service's commercial interest, and the arrangement should be capable of being described to a regulator without discomfort. Capacity must match intended volume, including the escalation and review workload rather than only initial consultations, since reviews accumulate as the cohort grows. Availability must cover escalation, so that a flagged case reaches a human within a defined period rather than when the prescriber next logs in. And the contract should address what happens when the prescriber declines, since a service whose economics depend upon approval rates has created exactly the pressure the frameworks exist to prevent.
The recruitment reality is that good prescribers assess the pharmacy as carefully as the pharmacy assesses them, and the services which attract them are the ones with proper protocols, working records and a realistic view of caseload. Governance built first is therefore also a recruitment asset, which is an argument for the sequence above beyond compliance.
How should the service be priced?
Against the cost of delivering it properly, rather than against the comparison sites, and per month of supply collected as supplied rather than as an upfront course.
The category's pricing dynamic is set out in the oral GLP-1 analysis, and the conclusion carries directly. Product margin is competed away, whilst the service layer is where a defensible position exists, so a price which covers only the medicine plus a thin margin has priced the monitoring at zero and will fund it out of goodwill until goodwill runs out.
Three principles follow. The review is part of the price and should never be discounted to the point where it reads as a formality, because it is simultaneously the safety mechanism and the retention mechanism. Introductory offers are acquisition spend and should be modelled against the actual retention curve rather than adopted because competitors use them. And the exit should be clean, since patients who can stop easily return more often than those who had to fight a cancellation process, and the alternative generates the disputes the consumer law guide describes.
What does the service look like at month eighteen?
Business cases model month three. The service is decided at month eighteen, and it looks materially different from the launch.
By then the cohort is mostly established rather than new, which inverts the workload. Reviews, monitoring, side-effect management, dose changes and discontinuation conversations exceed new consultations, and a staffing model built around acquisition is now mismatched to the work. Patients on maintenance ask different questions from patients starting. Some have plateaued and want to know why. Some want to stop and need that handled properly. Some have been lost to follow-up and should be recalled rather than quietly forgotten.
Two consequences deserve planning for at the outset. Prescriber capacity must scale with the cohort rather than with new starts, which is the arithmetic contracted arrangements most often fail to accommodate. And retention is the whole economics, so the measure which matters is the proportion still in treatment and still paying at month twelve and beyond, rather than conversion rate on the landing page.
A pharmacy which has modelled month eighteen honestly will build a smaller launch and a more durable service, which is close to the opposite of what the category's marketing encourages.
Where should you not economise?
Four lines, each of which is tempting to reduce and expensive to have reduced.
Verification. The category's defining failure is accepting self-reported measurements, and a service which economises here has built the thing regulators are looking for.
The record system. Evidencing a decision two years later is the difference between an audit and an investigation, and a service running on spreadsheets and inboxes cannot do it.
Prescriber time. Buying the minimum capacity produces the throughput pattern which regulators have publicly criticised, and the saving is small relative to what it risks.
The decline pathway. Handling refusals well costs something and returns more, since refused patients talk, review and return, and a refusal rate approaching zero is itself the warning.
When should you stop?
A build should define in advance what would cause it to be abandoned, because the decision is far harder once patients are enrolled and money is spent.
Four criteria are worth writing down before launch. If prescriber capacity cannot be secured on terms which preserve genuine independence, the service should not open. If verification cannot be operated at the intended volume, the volume should reduce or the service should not proceed. If the price required to fund proper monitoring cannot be achieved in the market the pharmacy serves, the model does not work regardless of demand. And if retention at month twelve falls materially below the level the business case required, the service should be reduced or closed rather than sustained by increasing acquisition spend.
Writing those down is unglamorous and it is the difference between a considered exit and a slow one. It is also, in this category particularly, the mark of an operator who has understood what they are entering.
Key takeaways
- The entry test is not whether demand exists but whether genuine verification and monitoring can be operated at the intended volume with a prescriber who can genuinely decline.
- Four structural choices determine everything downstream, comprising prescribing capacity, consultation model, corporate structure and supply arrangement, and each is easier to make than to unmake.
- Build the cost estimate from five unavoidable components rather than a headline figure, and include staff time and the pre-revenue period which are routinely omitted.
- Build governance and protocol first and promotion last, since every layer constrains the one beneath it and retrofitting verification into a live flow means existing patients were assessed without it.
- Price against the cost of delivering the service properly rather than against comparison sites, since product margin is competed away and the review is both the safety and the retention mechanism.
- Model month eighteen rather than month three, because reviews and monitoring will exceed new consultations and prescriber capacity must scale with the cohort rather than with new starts.
- Do not economise on verification, records, prescriber time or the decline pathway, and write down the kill criteria before launch rather than after enrolment.
FAQs
Governance first, funnel last.
The record system is the component this guide says not to economise on, because evidencing a decision two years later is the difference between an audit and an investigation. Dataforge PMR holds the questionnaire, the verification artefacts, the prescriber's reasoning and the review intervals on one patient journey, and fires the recalls a maturing cohort depends upon.
See Dataforge PMR